Contract research, development and manufacturing organisation (CRDMO) WuXi XDC Cayman has signed a memorandum of understanding with South Korea-based AbTis to advance next-generation antibody-drug conjugates (ADCs).
The partnership combines AbTis’ AbClick site-selective conjugation platform with WuXi XDC’s all-in-one development and manufacturing platform and discovery services.
Go deeper with GlobalData
AbClick leverages affinity peptide-assisted linkers for precise antibody-drug conjugation.
To expedite ADC therapeutic innovation, the collaboration will incorporate AbTis’ technology into WuXi XDC’s toolbox.
With the improvement of chemistry, manufacturing and controls (CMC) platform offerings, WuXi XDC and AbTis will enable clients to expedite the selection of preclinical candidates and the timelines of CMC development, as well as develop ADCs.
WuXi XDC will enable potential partnerships between AbTis and its network of clients.
WuXi XDC CEO Dr Jimmy Li stated: “This collaboration with AbTis underscores our commitment to advancing innovation through strategic partnerships and creating meaningful value for our clients.
“With the addition of AbTis’ innovative conjugation technology into the WuXi XDC technology suite, it will provide our clients with broader options of advanced bioconjugation technologies and tailormade solutions to support the advancement of next-generation ADCs and bioconjugate drugs.”
The initiative will widen the reach of AbTis technologies globally and pave the way for synergistic market opportunities.
AbTis CEO Dr Tae Dong Han stated: “This partnership with WuXi XDC marks a significant milestone for AbTis as we expand the reach of our site-selective conjugation technology.
“By leveraging WuXi XDC’s extensive global network and integrated CRDMO platforms alongside AbTis’ innovative bioconjugation technologies and comprehensive expertise, we aim to create a synergy that amplifies the accessibility and impact of our innovations.”
